BPBT
NBIX icon

Boston Private Bank & Trust’s Neurocrine Biosciences NBIX Stock Holding History

Boston Private Bank & Trust’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$8K Hold
200
– – ﹤0.01% 852
2014
Q4 		$4K Hold
200
– – ﹤0.01% 988
2014
Q3 		$3K Hold
200
– – ﹤0.01% 972
2014
Q2 		$3K Hold
200
– – ﹤0.01% 923
2014
Q1 		$3K Hold
200
– – ﹤0.01% 947
2013
Q4 		$2K Hold
200
– – ﹤0.01% 1008
2013
Q3 		$2K Hold
200
– – ﹤0.01% 939
2013
Q2 		$3K Buy
+200
New +$2.46K ﹤0.01% 888

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Boston Private Bank & Trust's NBIX Position: Q1 2015 in Review

Boston Private Bank & Trust held its Neurocrine Biosciences (NBIX) position steady in Q1 2015 at 200 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #852.

Boston Private Bank & Trust first reported a position in NBIX in Q2 2013 and has held it in 8 quarters since. 175 funds tracked by Wall St. Rank hold NBIX as of Q1 2015.

  • Boston Private Bank & Trust held 200 shares of Neurocrine Biosciences worth $8K as of Q1 2015.
  • Boston Private Bank & Trust left its Neurocrine Biosciences share count unchanged in Q1 2015.
  • Neurocrine Biosciences made up ﹤0.01% of Boston Private Bank & Trust's portfolio in Q1 2015, its #852 holding.
  • Boston Private Bank & Trust first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 8 quarters since.
  • 175 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2015.

Based on Boston Private Bank & Trust's 13F filing for Q1 2015, filed 9 Apr 2015.